

Lymph node status (Core)

Lymph node status is one of the most important prognostic factors for survival in patients with cervical cancer.¹ The 5-year survival rate decreases from 85 to 50% when lymph node metastases are identified.²

Radical hysterectomy or trachelectomy and pelvic lymphadenectomy are the standard of treatment in most centres for FIGO 2018 stage IB1, IB2 and IIA1 cervical carcinomas and, in some centres, for stage IA2 carcinomas. There is an increasing trend for a more conservative approach, such as loop/cone excision, in the treatment of FIGO stage IA2 and small stage IB1 carcinomas, particularly if additional risk factors such as lymphovascular invasion are absent. In such cases, lymphadenectomy is often performed. Lymphadenectomy may also occasionally be performed for bulky nodal metastases (>2 cm) which are resistant to radiotherapy and/or chemotherapy; debulking of enlarged pelvic nodes has been shown to reduce the risk of pelvic recurrence but does not benefit survival.^{3,4}

Core data items regarding lymph node status are restricted to the number of lymph nodes identified from the various sites and the number involved by tumour. However, some of the other parameters included below may be recorded if locally agreed and recording these parameters (size of lymph node metastasis, extracapsular spread, lymph node ratio) may be useful for future research.

Resected lymph nodes are categorised as regional (paracervical, parametrial, various pelvic lymph node groups, including obturator, internal, common or external iliac, presacral and lateral sacral, and para-aortic) or non-regional nodes (inguinal and other nodes)⁵ The FIGO 2018 staging system⁶, unlike previous systems, includes lymph node status and is thus now closely aligned with the structure of the TNM Classification (see **PATHOLOGICAL STAGING**). In the FIGO 2018 system, pelvic lymph node involvement is stage IIIC1 and para-aortic nodal involvement stage IIIC2. In applying a TNM stage, regional lymph node metastases contribute to the N category, but non-regional node involvement is regarded as distant metastasis. One point to emphasise is that the TNM8 Classification takes into account the size of the nodal metastasis in assigning the N category. According to TNM8, macrometastases (MAC) are >2mm, micrometastases (MIC) are >0.2-2 mm and isolated tumour cells (ITCs) are up to 0.2 mm. MAC are regarded as pN1, MIC as pN1 (mi) and ITCs are pN0 (i+). The 2018 FIGO staging originally stated that MIC and ITCs can be recorded but this does not alter the tumour stage.⁶ However, a corrigendum was later issued stating that MIC should be counted as nodal involvement and FIGO stage IIIC.⁷

According to the Union for International Cancer Control (UICC), a pelvic lymphadenectomy specimen will ordinarily include 6 or more lymph nodes, but if this node count is not met and the resected lymph nodes are negative, the carcinoma should still be classified as pN0. The mean or median number of lymph nodes removed during pelvic lymphadenectomy varies widely in different studies and ranges from 13 to 56 nodes. Apart from the arbitrary minimum number of nodes proposed by the UICC, there is no internationally accepted minimum for the number of resected lymph nodes required as part of a lymphadenectomy for cervical cancer. A study by Inoue et al reported that the number of positive nodes was of greater prognostic significance than the presence of nodal metastasis per se⁸ and a more recent study showed that the number of lymph nodes with metastases is an independent risk factor for reduced survival in patients with cervical cancer.⁹

In many centres, sentinel lymph node biopsy is now being undertaken in patients with presumed low-stage cervical carcinoma.¹⁰⁻¹² Overall, in stage I cervical cancer the incidence of pelvic lymph node metastasis is approximately 10%¹³ and if the sentinel lymph node is negative, this avoids the morbidity associated with full pelvic lymphadenectomy in the remaining 90% of patients, i.e. sentinel lymph node biopsy is of value in reducing the requirement for a complete lymphadenectomy with its attendant morbidity in a patient population at low risk for lymph node metastases. With regard to the issue of “MIC” (which, as discussed, should be staged as pN1 (mi)) and the use of immunohistochemistry (usually cytokeratin AE1/AE3), a study by Juretzka et al found immunohistochemically-detected MIC in 8.1% of patients with initially reported “negative” nodes (comprising 4 of 976 or 0.41% of pelvic lymph nodes examined).¹⁴ The immunohistochemically-detected MIC were more frequent in tumours with lymphovascular invasion; another study showed that immunohistochemically-detected MIC were a risk factor for tumour recurrence.¹⁵ Other studies have shown higher rates of lymph node MIC in early stage cervical carcinomas for example, 10.1% of cases in a study by Cibula et al¹⁶ and 15% in a study by Lentz and co-workers.¹⁷ The latter study also showed that MIC were more likely in patients in whom larger numbers of lymph nodes were removed. A study by Horn et al revealed that lymph node MIC were prognostically significant; patients with MIC had a reduced 5-year survival rate compared with node-negative patients, but fared better than those patients with MAC.¹⁸ In the study by Cibula et al¹⁶ ITCs were detected in

4.5% of cases and were found to be of no prognostic significance. If sentinel lymph node biopsy is carried out, the number of nodes examined and the number of positive nodes should be recorded. It is acknowledged that there are few published data regarding MIC and ITCs in cervical cancer and until further data emerge it is recommended that these should be reported in the same way as ITCs at other sites.

The size of lymph nodes with metastatic carcinoma has been reported to be a prognostic factor in one study; patients with lymph nodes >15 mm in short-axis diameter had significantly lower survival rates than nodes of smaller size.¹⁹

Lymph node ratio (LNR), the ratio of positive to negative lymph nodes, has been assessed in a wide range of different cancers. The significance of LNR in cervical carcinoma has only recently been evaluated and there is insufficient evidence to include this as a data item in the current dataset. However, in early stage cervical cancer, the LNR identifies node-positive patients with a worse prognosis²⁰ and has been found to be an independent prognostic indicator of overall survival and disease-free survival in patients with SCC.²¹

There are very few studies that assess the significance of extracapsular/extranodal spread of metastatic cervical carcinoma, and the item has not been included in this dataset. One study showed extracapsular spread to correlate with advanced stage disease, the number of involved nodes and the size of metastatic deposits.²² In another study, patients with extracapsular lymph node spread had a significantly lower 5-year recurrence-free survival rate compared to patients whose nodes showed no extracapsular spread.²³

The lymph node parameters considered in the last 3 paragraphs have not been included as specific data items due to a lack of supporting evidence. However, as indicated above, individual pathologists or institutions may choose to include some or all of these items in their own protocols. This may be useful for prospective data collection.

References

- 1 Uno T, Ito H, Itami J, Yasuda S, Isobe K, Hara R, Sato T, Minoura S, Shigematsu N and Kubo A (2000). Postoperative radiation therapy for stage IB-IIb carcinoma of the cervix with poor prognostic factors. *Anticancer Res* 20(3b):2235-2239.
- 2 Peters WA, 3rd, Liu PY, Barrett RJ, 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W, Jr. and Alberts DS (2000). Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *J Clin Oncol* 18(8):1606-1613.
- 3 Cheung TH, Lo KW, Yim SF, Yau SH, Yu MM and Yeung WK (2011). Debulking metastatic pelvic nodes before radiotherapy in cervical cancer patients: a long-term follow-up result. *Int J Clin Oncol* 16(5):546-552.
- 4 Yaegashi N, Sato S, Inoue Y, Noda K and Yajima A (1994). Conservative surgical treatment in cervical cancer with 3 to 5 mm stromal invasion in the absence of confluent invasion and lymph-vascular space involvement. *Gynecol Oncol* 54(3):333-337.
- 5 Sobin L, Gospodarowicz M, Wittekind C and International Union against Cancer (eds) (2009). *TNM Classification of Malignant Tumours*, Wiley-Blackwell, Chichester, UK and Hoboken, New Jersey.
- 6 Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, Kehoe ST, Konishi I, Olawaiye AB, Prat J, Sankaranarayanan R, Brierley J, Mutch D, Querleu D, Cibula D, Quinn M, Botha H, Sigurd L, Rice L, Ryu HS, Ngan H, Maenpaa J, Andrijono A, Purwoto G, Maheshwari A, Bafna UD, Plante M and Natarajan J (2019). Revised FIGO staging for carcinoma of the cervix uteri. *Int J Gynaecol Obstet* 145(1):129-135.
- 7 Corrigendum to "Revised FIGO staging for carcinoma of the cervix uteri" [Int J Gynecol Obstet 145(2019) 129-135]. (2019) *Int J Gynaecol Obstet* 147(2):279-280.
- 8 Inoue T and Morita K (1990). The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB. *Cancer* 65(9):1923-1927.
- 9 Park JW and Bae JW (2016). Prognostic significance of positive lymph node number in early cervical cancer. *Mol Clin Oncol* 4(6):1052-1056.

- 10 Gortzak-Uzan L, Jimenez W, Nofech-Mozes S, Ismiil N, Khalifa MA, Dube V, Rosen B, Murphy J, Laframboise S and Covens A (2010). Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard? *Gynecol Oncol* 116(1):28-32.
- 11 van de Lande J, Torrenge B, Raijmakers PG, Hoekstra OS, van Baal MW, Brolmann HA and Verheijen RH (2007). Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. *Gynecol Oncol* 106(3):604-613.
- 12 Andikyan V, Khoury-Collado F, Denesopolis J, Park KJ, Hussein YR, Brown CL, Sonoda Y, Chi DS, Barakat RR and Abu-Rustum NR (2014). Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: is less enough? *Int J Gynecol Cancer* 24(1):113-117.
- 13 Steed H, Rosen B, Murphy J, Laframboise S, De Petrillo D and Covens A (2004). A comparison of laparoscopic-assisted radical vaginal hysterectomy and radical abdominal hysterectomy in the treatment of cervical cancer. *Gynecol Oncol* 93(3):588-593.
- 14 Juretzka MM, Jensen KC, Longacre TA, Teng NN and Husain A (2004). Detection of pelvic lymph node micrometastasis in stage IA2-IB2 cervical cancer by immunohistochemical analysis. *Gynecol Oncol* 93(1):107-111.
- 15 Colturato LF, Signorini Filho RC, Fernandes RC, Gebrim LH and Oliani AH (2016). Lymph node micrometastases in initial stage cervical cancer and tumoral recurrence. *Int J Gynaecol Obstet* 133(1):69-75.
- 16 Cibula D, Abu-Rustum NR, Dusek L, Zikan M, Zaal A, Sevcik L, Kenter GG, Querleu D, Jach R, Bats AS, Dyduch G, Graf P, Klat J, Lacheta J, Meijer CJ, Mery E, Verheijen R and Zweemer RP (2012). Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. *Gynecol Oncol* 124(3):496-501.
- 17 Lentz SE, Muderspach LI, Felix JC, Ye W, Groshen S and Amezcua CA (2004). Identification of micrometastases in histologically negative lymph nodes of early-stage cervical cancer patients. *Obstet Gynecol* 103(6):1204-1210.
- 18 Horn LC, Hentschel B, Fischer U, Peter D and Bilek K (2008). Detection of micrometastases in pelvic lymph nodes in patients with carcinoma of the cervix uteri using step sectioning: Frequency, topographic distribution and prognostic impact. *Gynecol Oncol* 111(2):276-281.
- 19 Song S, Kim JY, Kim YJ, Yoo HJ, Kim SH, Kim SK, Lim MC, Kang S, Seo SS and Park SY (2013). The size of the metastatic lymph node is an independent prognostic factor for the patients with cervical cancer treated by definitive radiotherapy. *Radiotherapy and oncology* 108(1):168-173.
- 20 Fleming ND, Frumovitz M, Schmeler KM, dos Reis R, Munsell MF, Eifel PJ, Soliman PT, Nick AM, Westin SN and Ramirez PT (2015). Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. *Gynecol Oncol* 136(1):48-53.
- 21 Li C, Liu W and Cheng Y (2016). Prognostic significance of metastatic lymph node ratio in squamous cell carcinoma of the cervix. *Onco Targets Ther* 9:3791-3797.
- 22 Horn L-C, Hentschel B, Galle D and Bilek K (2008). Extracapsular extension of pelvic lymph node metastases is of prognostic value in carcinoma of the cervix uteri. *Gynecologic Oncology* 108:63-67.
- 23 Metindir J and Bilir Dilek G (2008). Evaluation of prognostic significance in extracapsular spread of pelvic lymph node metastasis in patients with cervical cancer. *Eur J Gynaecol Oncol* 29(5):476-478.